Retrospective cohort study demonstrates the diagnostic utility of combined antibodies in seronegative rheumatoid arthritis, highlighting prognostic implications.
Seronegative rheumatoid arthritis (SNRA), defined by the absence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), poses a persistent diagnostic challenge. Anti-carbamylated protein antibodies (Anti-CarP-IgG) and anti-RA33 antibodies targeting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP-A2/B1) have been proposed as supplementary biomarkers, yet their combined diagnostic utility in SNRA remains insufficiently characterized. A retrospective cohort study enrolled 550 RA patients (2010 ACR/EULAR criteria) at a single tertiary center (2024–2025). Patients were stratified into SNRA (RF-IgM < 14 IU/mL and ACPA < 5 U/mL; n = 189) and seropositive RA (SPRA; n = 361). Anti-CarP-IgG and Anti-RA33-IgG were measured by ELISA (positivity cutoff > 20 U/mL). Disease activity was assessed by DAS28-ESR/CRP; radiographic damage by modified Sharp/van der Heijde score and Larsen staging. Odds ratios (OR) with 95% confidence intervals (CI) were computed; Bonferroni correction was applied for multiple comparisons. Anti-RA33-IgG positivity was significantly lower in SNRA versus SPRA (15.9% vs. 29.9%, p < 0.001; OR 2.26, 95% CI 1.44–3.55), as was Anti-CarP-IgG positivity (10.6% vs. 23.0%, p = 0.001; OR 2.52, 95% CI 1.49–4.26). Combined testing identified at least one novel antibody in 23.8% of SNRA patients versus 45.2% of SPRA patients ( p < 0.001). Within SNRA, Anti-CarP-IgG-positive patients showed significantly more advanced radiographic staging: Stage IV prevalence was 25.0% vs. 7.1% in Anti-CarP-IgG-negative patients (OR 4.36, 95% CI 1.35–14.05, p = 0.021), despite equivalent DAS28-ESR ( p = 0.902). Combined Anti-CarP-IgG and Anti-RA33-IgG testing captures serological evidence in nearly one-quarter of SNRA patients. Anti-CarP-IgG positivity associates with a 4.4-fold increased odds of Stage IV radiographic disease, supporting its role as a prognostic stratification tool in SNRA.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: